The global threat of the spread of carbapenem resistance in Enterobacteriaceae has led to
the search for new antibacterials. Intravenous meropenem/vaborbactam (Vabomere™) is …

There has been a worldwide increase in infections caused by drug-resistant Gram-negative
pathogens, including carbapenem-resistant Enterobacteriaceae (CRE). Meropenem …

Meropenem–vaborbactam is a fixed-dose combination product of a carbapenem and a
cyclic boronic acid β-lactamase inhibitor with potent in vitro activity against Klebsiella …

Objective: To review the pharmacology, spectrum of activity, pharmacokinetics,
pharmacodynamics, safety, efficacy, administration, and considerations for clinical use of …

Vaborbactam is a member of a new class of β-lactamase inhibitors with inhibitory activity
against serine carbapenemases (eg, Klebsiella pneumoniae carbapenemase) that has …

Carbapenem-resistant gram-negative pathogens remain an urgent public health threat, and
safe, effective treatment options are limited. Although several agents are now available to …

Vaborbactam is a novel beta-lactamase inhibitor with activity against important beta-
lactamases, in particular, serine carbapenemases, and is currently approved in combination …

Carbapenem-resistant Enterobacteriaceae (CRE) has been declared as one of the most
urgent drug-resistant threats to the United States. 1 Resistance can occur through several …

Vaborbactam (VAB; formerly RPX7009) is a novel beta‐lactamase inhibitor based on a
cyclic boronic acid pharmacophore with potent inhibitory activity against Ambler class A and …

Introduction infections due to carbapenem-resistant Enterobacterales (CRE) constitute a
worldwide threat and are associated with significant mortality, especially in fragile patients …